{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-039083","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.143038+00:00","generated_at":"2026-06-15T02:26:46.922422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Citius Q2 FY2023 net loss $10.5M ($0.07/share); Halo-Lido Phase 2b topline expected Q2 2023","bullets":["Net loss of $10.5M ($0.07 per share) for fiscal Q2 ended March 31, 2023, vs $7.6M ($0.05) a year ago.","Cash $29.1M as of March 31, 2023; raised $15M in May 2023 registered direct offering, extending runway through May 2024.","Halo-Lido Phase 2b hemorrhoid trial completed; topline results expected by end of calendar Q2 2023.","Mino-Lok Phase 3 trial at 85 of 92 required events; enrollment ongoing aiming for completion in 2023.","I/ONTAK BLA under FDA review with PDUFA date July 28, 2023; spinoff preparation continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-039083","json":"https://secwatch.observer/filing/0001213900-23-039083.json","markdown":"https://secwatch.observer/filing/0001213900-23-039083.md","text":"https://secwatch.observer/filing/0001213900-23-039083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/0001213900-23-039083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/ea178475-8k_citiuspharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:26:46.922422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44566a3479804a9e21c9dd29364840087fcce173","claim":"Citius Pharmaceuticals, Inc. reported the fiscal second quarter ended March 31, 2023 results: net income Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March, EPS ($0.07) and ($0.10) per share.","evidence_excerpt":"r ($0.07) and ($0.10) per share for the three and six months ended March 31, 2023, respectively, compared to a net loss of $7.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/0001213900-23-039083-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal second quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March"},{"label":"EPS","value":"($0.07) and ($0.10) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}